Utilizing Advanced Tools to Minimize the Burden of Cytomegalovirus (CMV) in Transplant Recipients
WebcastFaculty
OVERVIEW
Utilizing Advanced Tools to Minimize the Burden of Cytomegalovirus (CMV) in Transplant Recipients is organized by Vemco MedEd, LLC and will be held during Aug 03, 2017 - Aug 03, 2018.
The target audience for this medical event is for all healthcare providers involved in the management of these patients to prevent and treat CMV viremia. Therefore, this continuing medical education activity targets ID clinicians involved in the care of transplant recipients. These include ID physicians and pharmacists, nurses, microbiologists and allied healthcare providers. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Overview :
Advances in medicine have made the use of solid organ and stem cell transplantation viable options for long-term clinical success for a variety of serious medical conditions. However, transplant recipients remain at higher risk of severe complications due to immunosuppressive regimens, particularly opportunistic infections caused by a variety of pathogens. Cytomegalovirus (CMV) remains a significant pathogen post transplantation. Long-term clinical success post-transplantation will require effective prevention and treatment of CMV infection (i.e., asymptomatic stage) and CMV disease (i.e., presence of symptoms). Prevention can be accomplished through antiviral prophylaxis or pre-emptive approaches. Treatment of CMV disease is also increasingly challenging with the presence of CMV exhibiting resistance to traditional antiviral agents (e.g., ganciclovir). Clinicians must be aware of the latest technologies and new agents that can be used to optimize long-term patient outcomes following transplantation. Conference Objectives are :
• Recognize the burden of CMV and identify risk factors for CMV infection and disease.
• Evaluate the benefits and risks of antiviral prophylaxis versus pre-emptive approaches in the prevention of CMV.
• Assess the utility of advanced diagnostic monitoring tools to guide medical decision-making for patients with or at risk of CMV.
• Describe the mechanisms of CMV resistance and assess the potential role of newer and emerging antiviral agents in overcoming resistance.
Additional details will be posted as soon as they are available.
The target audience for this medical event is for all healthcare providers involved in the management of these patients to prevent and treat CMV viremia. Therefore, this continuing medical education activity targets ID clinicians involved in the care of transplant recipients. These include ID physicians and pharmacists, nurses, microbiologists and allied healthcare providers. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Overview :
Advances in medicine have made the use of solid organ and stem cell transplantation viable options for long-term clinical success for a variety of serious medical conditions. However, transplant recipients remain at higher risk of severe complications due to immunosuppressive regimens, particularly opportunistic infections caused by a variety of pathogens. Cytomegalovirus (CMV) remains a significant pathogen post transplantation. Long-term clinical success post-transplantation will require effective prevention and treatment of CMV infection (i.e., asymptomatic stage) and CMV disease (i.e., presence of symptoms). Prevention can be accomplished through antiviral prophylaxis or pre-emptive approaches. Treatment of CMV disease is also increasingly challenging with the presence of CMV exhibiting resistance to traditional antiviral agents (e.g., ganciclovir). Clinicians must be aware of the latest technologies and new agents that can be used to optimize long-term patient outcomes following transplantation. Conference Objectives are :
• Recognize the burden of CMV and identify risk factors for CMV infection and disease.
• Evaluate the benefits and risks of antiviral prophylaxis versus pre-emptive approaches in the prevention of CMV.
• Assess the utility of advanced diagnostic monitoring tools to guide medical decision-making for patients with or at risk of CMV.
• Describe the mechanisms of CMV resistance and assess the potential role of newer and emerging antiviral agents in overcoming resistance.
Additional details will be posted as soon as they are available.
SPECIALITIES
Infectious Disease
Quick Links